OBJECTIVE: To determine the clinical features of lung cancer patients with respiratory tuberculosis (TB), thereby elucidating the clinical course. SETTING: A tertiary referral hospital in Korea, with intermediate TB prevalence. DESIGN: A retrospective case-control study involving lung cancer patients in whom respiratory TB was diagnosed concurrently or sequentially. RESULTS: Of 36 lung cancer patients, 10 (27.8%) were diagnosed with TB concurrently with the diagnosis of lung cancer, while 26 (72.2%) were diagnosed with TB after the diagnosis of lung cancer. The median time from the diagnosis of lung cancer to the diagnosis of TB was 4 months (range -1-47). Five lung cancer patients presented with incidental microbiological or pathological findings. Of the 36 lung cancer patients, eight (22%) had no remarkable changes on chest radiography, while all control group patients had identifiable abnormalities (P < 0.001). In both groups, most patients completed the initially prescribed anti-tuberculosis medications, with some modest modifications. The most common cause of death in the lung cancer group was progression of lung cancer (89.5%). CONCLUSION: The clinical course of respiratory TB in lung cancer patients does not differ from that in patients without malignancy, suggesting that respiratory TB may not influence the clinical course of lung cancer patients if properly treated.
OBJECTIVE: To determine the clinical features of lung cancerpatients with respiratory tuberculosis (TB), thereby elucidating the clinical course. SETTING: A tertiary referral hospital in Korea, with intermediate TB prevalence. DESIGN: A retrospective case-control study involving lung cancerpatients in whom respiratory TB was diagnosed concurrently or sequentially. RESULTS: Of 36 lung cancerpatients, 10 (27.8%) were diagnosed with TB concurrently with the diagnosis of lung cancer, while 26 (72.2%) were diagnosed with TB after the diagnosis of lung cancer. The median time from the diagnosis of lung cancer to the diagnosis of TB was 4 months (range -1-47). Five lung cancerpatients presented with incidental microbiological or pathological findings. Of the 36 lung cancerpatients, eight (22%) had no remarkable changes on chest radiography, while all control group patients had identifiable abnormalities (P < 0.001). In both groups, most patients completed the initially prescribed anti-tuberculosis medications, with some modest modifications. The most common cause of death in the lung cancer group was progression of lung cancer (89.5%). CONCLUSION: The clinical course of respiratory TB in lung cancerpatients does not differ from that in patients without malignancy, suggesting that respiratory TB may not influence the clinical course of lung cancerpatients if properly treated.
Authors: Dmitry Giller; Boris Giller; Galina Scherbakova; Elizaveta V Mikhaylenko; Liudmila M Mikhaleva; Vladimir N Nikolenko; Liliya V Gavryushova; Siva G Somasundaram; Cecil E Kirkland; Gjumrakch Aliev Journal: BMC Pulm Med Date: 2020-07-18 Impact factor: 3.317
Authors: Denise Rossato Silva; Dirceu Felipe Valentini; Alice Mânica Müller; Carlos Podalirio Borges de Almeida; Paulo de Tarso Roth Dalcin Journal: J Bras Pneumol Date: 2013 Jun-Aug Impact factor: 2.624